electroCore, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ECOR research report →
Price Chart
About the company
electroCore, Inc. is a commercial-phase medical device enterprise whose focus lies in developing and bringing to market a variety of non-invasive vagus nerve stimulation (nVNS) therapies. Currently, the firm is advancing gammaCore, a prescription-only nVNS therapy specifically engineered for adults to acutely treat the discomfort associated with both migraine and episodic cluster headaches.
- CEO
- Joshua Lev
- IPO
- 2018
- Employees
- 83
- HQ
- Rockaway, NJ, US
Get TickerSpark's AI analysis on ECOR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $40.78M
- P/E
- -3.39
- Fwd P/E
- 9.56
- PEG
- -0.19
- P/S
- 1.18
- P/B
- 0.00
- EV/EBITDA
- -4.58
- Div Yield
- 0.00%
- Gross Margin
- 87.67%
- Op Margin
- -33.15%
- Net Margin
- -33.46%
- ROE
- 498.83%
- ROIC
- -170.03%
Latest fiscal year · YoY change
- Revenue
- $32.03M+27.2%
- Gross Profit
- $27.79M+29.9%
- Op Income
- $-13,153,000
- Net Income
- $-13,966,000-17.5%
- EPS
- $-1.65-3.8%
- OCF Growth
- -17.8%
- FCF Growth
- -18.8%
- 52W High
- $12.70
- 52W Low
- $3.90
- 50D MA
- $8.56
- 200D MA
- $7.70
- Beta
- 1.05
- RSI (14)
- 29
- Avg Volume
- 120.32K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
electroCore posted record third-quarter sales and its smallest operating loss ever, while trimming 2026 revenue guidance as it shifts expected growth into 2027.· November 4, 2026
- Record Q3 net sales of $9.7 million, up about 12% year over year, with gross margin expanding to 88.5%.
- Adjusted EBITDA loss improved to $700,000, the company’s best result to date, and operating loss narrowed to $1.6 million.
- Management cut full-year 2026 revenue guidance to $39 million to $42 million, saying the sales-force changes are taking longer than planned.
- The company expects accelerated growth in 2027, with preliminary revenue growth guidance of 30% to 40% year over year and a path to first positive adjusted EBITDA by the end of 2027.
- electroCore filed a 510(k) for Quell in CIPN and views that as incremental upside, not something embedded in 2027 guidance.
electroCore reported third-quarter 2026 net sales of $9.7 million versus $8.7 million a year ago, up approximately 12%. Gross profit was $8.6 million, gross margin was 88.5% versus 86% in the prior-year period and 86.5% in Q2, and loss from operations narrowed to $1.6 million. GAAP net loss was $1.3 million, or $0.13 per share, versus $3.4 million, or $0.40 per share, in Q3 2025; adjusted EBITDA net loss improved to $700,000 from $2 million a year ago. For full-year 2026, management revised revenue guidance to $39 million to $42 million, down from prior guidance of greater than 30% year-over-year growth, citing timing shifts into 2027. Management also said preliminary 2027 revenue growth guidance is 30% to 40% year over year, with an expectation of first positive adjusted EBITDA by the end of 2027 without a new dilutive equity financing, assuming execution and current capital resources.
The CEO/co-CEO message was that the company is deliberately sacrificing some near-term growth to build a more durable, profitable business. He emphasized that the sales organization was restructured on purpose, with more coverage, smaller territories, and more accountability, and said the early indicators suggest the model is working. Tone was cautious but confident: the timing has moved, but the conviction in the strategy has not.
The CFO highlighted the quarter’s financial improvement: sales of $9.7 million, gross margin of 88.5%, operating loss of $1.6 million, and adjusted EBITDA loss of $700,000. He attributed the improved quarter to stronger product mix, lower R&D spend of $400,000 versus $700,000 a year ago, and SG&A of $9.7 million, essentially flat year over year and down from $10.1 million in Q2. He also noted cash, cash equivalents and marketable securities of about $7.5 million at quarter-end versus about $10 million at June 30, and said inventories rose to $4 million from $1.6 million at year-end to support forecasted growth; he added the company is evaluating refinancing its term loan to extend principal repayments.
Analysts focused on whether the new revenue guide implies an achievable sequential ramp, and management said confidence comes from more fully staffed VA coverage, newer reps proving more productive and faster to ramp, and better internal tools to drive refills. Questions on CIPN centered on timing, commercial strategy and whether 2027 guidance includes the indication; management said CIPN would be upside, with any FDA response likely no earlier than the second half of the first quarter and no additional trials currently planned. Management also said the 483 letter should not delay CIPN review, and that Quell’s OTC version remains a possibility but is delayed while the company prioritizes profitable revenue.
The bullish case from the call is that electroCore is showing real operating leverage: revenue hit a record, margins expanded, and losses improved materially. Management also pointed to stronger field metrics, such as faster ramping reps, better VA penetration, and improving refill trends, suggesting the commercial reset may be gaining traction. CIPN, if cleared, could add a new indication to a product management already believes has room to grow.
The main risk is timing: management explicitly cut 2026 revenue guidance because the sales-force changes are taking longer than expected and pushed the acceleration into 2027. Cash ended the quarter at about $7.5 million, inventories were built up to support growth, and management is still considering term-loan refinancing, which underscores balance-sheet sensitivity. The FDA remains a key uncertainty for CIPN and OTC Quell, and management repeatedly acknowledged that review timing and outcomes are not under their control.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 67.1%
- Shares Outstanding
- 9.23M
- Float Shares
- 6.19M
of shares held by institutions
33 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Wexford Capital LP | 293.90K | ▲ 201.84K |
| Vanguard Group Inc | 242.94K | ▲ 9.47K |
| Vanguard Capital Management LLC | 211.64K | 0 |
| Fourworld Capital Management LLC | 165.65K | ▲ 71.65K |
| Citadel Advisors LLC | 158.71K | ▲ 114.91K |
| Geode Capital Management, LLC | 68.18K | ▼ 4.97K |
| Jaffetilchin Investment Partners, LLC | 59.95K | 0 |
| Quadrature Capital Ltd | 54.83K | ▲ 54.83K |
| Wealthspire Advisors, LLC | 46.68K | ▼ 819 |
| Vanguard Fiduciary Trust Co | 38.77K | 0 |
| Hightower Advisors, LLC | 35.34K | 0 |
| Blackrock, Inc. | 34.00K | ▲ 2.23K |
Held by 23 ETFs
Biggest fund positions in ECOR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | Fox Michael | buy | 2,500 |
| Nov 12, 26 | Errico Thomas J. | buy | 10,000 |
| Sep 14, 26 | Errico Thomas J. | buy | 5,000 |
| Sep 11, 26 | Fox Michael | buy | 5,000 |
| Sep 11, 26 | Fox Michael | other | 5,000 |
| Sep 9, 26 | Theofilos James Charles | other | 11,123 |
| Sep 9, 26 | Wilber Patricia | other | 11,123 |
| Sep 9, 26 | Bonfiglioli Elena | other | 11,123 |
| Sep 8, 26 | Fox Michael | other | 55,000 |
| Sep 9, 26 | Goldstein Julie Ann | other | 11,123 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ECOR coverage
Recent articles, reports, and earnings notes.
No research on ECOR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ECOR report →Randomized Study of Non-Invasive Autonomic Neuromodulation for Long COVID Published Online in Neuromodulation
globenewswire.com · Nov 12
electroCore (ECOR) Upgraded to Buy: Here's What You Should Know
zacks.com · Nov 9
electroCore to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
globenewswire.com · Nov 5
electroCore, Inc. (ECOR) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 4
electroCore, Inc. (ECOR) Reports Q3 Loss, Misses Revenue Estimates
zacks.com · Nov 4
electroCore Q3 Earnings Call Highlights
marketbeat.com · Nov 4
electroCore Announces Third Quarter 2026 Financial Results
globenewswire.com · Nov 4
electroCore to Announce Third Quarter September 30, 2026, Financial Results on Wednesday, November 4, 2026
globenewswire.com · Oct 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.